Antonio Villaverde

List of Publications by Year in Descending Order

322 papers	9,227 citations	51 h-index	80 g-index
354 ext. papers	10,270 ext. citations	6.6 avg, IF	6.28 L-index

#	Paper	IF	Citations
322	CXCR4-targeted nanotoxins induce GSDME-dependent pyroptosis in head and neck squamous cell carcinoma.. *Journal of Experimental and Clinical Cancer Research*, **2022**, 41, 49	12.8	3
321	Engineering non-antibody human proteins as efficient scaffolds for selective, receptor-targeted drug delivery.. *Journal of Controlled Release*, **2022**, 343, 277-277	11.7	0
320	A diphtheria toxin-based nanoparticle achieves specific cytotoxic effect on CXCR4 lymphoma cells without toxicity in immunocompromised and immunocompetent mice.. *Biomedicine and Pharmacotherapy*, **2022**, 150, 112940	7.5	1
319	Toxicity Profiling of Bacterial Inclusion Bodies in Human Caco-2 Cells.. *Frontiers in Bioengineering and Biotechnology*, **2022**, 10, 842256	5.8	1
318	GSDMD-dependent pyroptotic induction by a multivalent CXCR4-targeted nanotoxin blocks colorectal cancer metastases.. *Drug Delivery*, **2022**, 29, 1384-1397	7	2
317	A multivalent Ara-C-prodrug nanoconjugate achieves selective ablation of leukemic cells in an acute myeloid leukemia mouse model. *Biomaterials*, **2021**, 280, 121258	15.6	2
316	Antibacterial Activity of T22, a Specific Peptidic Ligand of the Tumoral Marker CXCR4. *Pharmaceutics*, **2021**, 13,	6.4	1
315	Self-assembling protein nanocarrier for selective delivery of cytotoxic polypeptides to CXCR4+ head and neck squamous cell carcinoma tumors. *Acta Pharmaceutica Sinica B*, **2021**,	15.5	3
314	Ion-dependent slow protein release from disintegrating micro-granules. *Drug Delivery*, **2021**, 28, 2383-2391	7	2
313	Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4 Diffuse Large B-Cell Lymphoma Cells. *International Journal of Nanomedicine*, **2021**, 16, 1869-1888	7.3	5
312	In Vitro Fabrication of Microscale Secretory Granules. *Advanced Functional Materials*, **2021**, 31, 2100914	15.6	6
311	Selecting Subpopulations of High-Quality Protein Conformers among Conformational Mixtures of Recombinant Bovine MMP-9 Solubilized from Inclusion Bodies. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	5
310	Self-Assembled Nanobodies as Selectively Targeted, Nanostructured, and Multivalent Materials. *ACS Applied Materials & Interfaces*, **2021**, 13, 29406-29415	9.5	1
309	Biparatopic Protein Nanoparticles for the Precision Therapy of CXCR4 Cancers. *Cancers*, **2021**, 13,	6.6	2
308	Design and engineering of tumor-targeted, dual-acting cytotoxic nanoparticles. *Acta Biomaterialia*, **2021**, 119, 312-322	10.8	6
307	Title: insoluble proteins catch heterologous soluble proteins into inclusion bodies by intermolecular interaction of aggregating peptides. *Microbial Cell Factories*, **2021**, 20, 30	6.4	3
306	Engineering the Performance of Artificial Inclusion Bodies Built of Catalytic Galactosidase. *ACS Sustainable Chemistry and Engineering*, **2021**, 9, 2552-2558	8.3	7

305	Extracellular vesicles from recombinant cell factories improve the activity and efficacy of enzymes defective in lysosomal storage disorders. *Journal of Extracellular Vesicles*, **2021**, 10, e12058	16.4	7
304	Antineoplastic effect of a diphtheria toxin-based nanoparticle targeting acute myeloid leukemia cells overexpressing CXCR4. *Journal of Controlled Release*, **2021**, 335, 117-129	11.7	6
303	Insights on the emerging biotechnology of histidine-rich peptides. *Biotechnology Advances*, **2021**, 54, 107817	17.8	4
302	Biofabrication of functional protein nanoparticles through simple His-tag engineering. *ACS Sustainable Chemistry and Engineering*, **2021**, 9, 12341-12354	8.3	4
301	Rational engineering of a human GFP-like protein scaffold for humanized targeted nanomedicines. *Acta Biomaterialia*, **2021**, 130, 211-222	10.8	3
300	Tolerability to non-endosomal, micron-scale cell penetration probed with magnetic particles. *Colloids and Surfaces B: Biointerfaces*, **2021**, 208, 112123	6	
299	Developing Protein-Antitumoral Drug Nanoconjugates as Bifunctional Antimicrobial Agents. *ACS Applied Materials & Interfaces*, **2020**, 12, 57746-57756	9.5	3
298	Recombinant Protein-Based Nanoparticles: Elucidating their Inflammatory Effects In Vivo and their Potential as a New Therapeutic Format. *Pharmaceutics*, **2020**, 12,	6.4	6
297	Engineering Protein Nanoparticles Out from Components of the Human Microbiome. *Small*, **2020**, 16, e2001885	11	8
296	The Biological Potential Hidden in Inclusion Bodies. *Pharmaceutics*, **2020**, 12,	6.4	13
295	A refined cocktailing of pro-apoptotic nanoparticles boosts anti-tumor activity. *Acta Biomaterialia*, **2020**, 113, 584-596	10.8	9
294	Nanostructured recombinant protein particles raise specific antibodies against the nodavirus NNV coat protein in sole. *Fish and Shellfish Immunology*, **2020**, 99, 578-586	4.3	6
293	Nanostructured toxins for the selective destruction of drug-resistant human CXCR4 colorectal cancer stem cells. *Journal of Controlled Release*, **2020**, 320, 96-104	11.7	28
292	Stable anchoring of bacteria-based protein nanoparticles for surface enhanced cell guidance. *Journal of Materials Chemistry B*, **2020**, 8, 5080-5088	7.3	7
291	Endosomal escape of protein nanoparticles engineered through humanized histidine-rich peptides. *Science China Materials*, **2020**, 63, 644-653	7.1	11
290	Engineering Secretory Amyloids for Remote and Highly Selective Destruction of Metastatic Foci. *Advanced Materials*, **2020**, 32, e1907348	24	25
289	Artificial Inclusion Bodies for Clinical Development. *Advanced Science*, **2020**, 7, 1902420	13.6	21
288	Engineering a Nanostructured Nucleolin-Binding Peptide for Intracellular Drug Delivery in Triple-Negative Breast Cancer Stem Cells. *ACS Applied Materials & Interfaces*, **2020**, 12, 5381-5388	9.5	10

287	Self-assembling as regular nanoparticles dramatically minimizes photobleaching of tumour-targeted GFP. *Acta Biomaterialia*, **2020**, 103, 272-280	10.8	7
286	Divalent Cations: A Molecular Glue for Protein Materials. *Trends in Biochemical Sciences*, **2020**, 45, 992-1003	16.3	16
285	Aggregation-prone peptides modulate activity of bovine interferon gamma released from naturally occurring protein nanoparticles. *New Biotechnology*, **2020**, 57, 11-19	6.4	8
284	Potential of MMP-9 based nanoparticles at optimizing the cow dry period: pulling apart the effects of MMP-9 and nanoparticles. *Scientific Reports*, **2020**, 10, 11299	4.9	4
283	Release of functional fibroblast growth factor-2 from artificial inclusion bodies. *Journal of Controlled Release*, **2020**, 327, 61-69	11.7	10
282	Nanostructured antimicrobial peptides: The last push towards clinics. *Biotechnology Advances*, **2020**, 44, 107603	17.8	36
281	Fluorescent Dye Labeling Changes the Biodistribution of Tumor-Targeted Nanoparticles. *Pharmaceutics*, **2020**, 12,	6.4	13
280	In Vivo Bactericidal Efficacy of GWH1 Antimicrobial Peptide Displayed on Protein Nanoparticles, a Potential Alternative to Antibiotics. *Pharmaceutics*, **2020**, 12,	6.4	4
279	Controlling self-assembling and tumor cell-targeting of protein-only nanoparticles through modular protein engineering. *Science China Materials*, **2020**, 63, 147-156	7.1	8
278	A CXCR4-targeted nanocarrier achieves highly selective tumor uptake in diffuse large B-cell lymphoma mouse models. *Haematologica*, **2020**, 105, 741-753	6.6	25
277	An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination. *Journal of Hematology and Oncology*, **2020**, 13, 36	22.4	26
276	Selective delivery of T22-PE24-H6 to CXCR4 diffuse large B-cell lymphoma cells leads to wide therapeutic index in a disseminated mouse model. *Theranostics*, **2020**, 10, 5169-5180	12.1	20
275	Engineering Protein Venoms as Self-Assembling CXCR4-Targeted Cytotoxic Nanoparticles. *Particle and Particle Systems Characterization*, **2020**, 37, 2000040	3.1	7
274	Collaborative membrane activity and receptor-dependent tumor cell targeting for precise nanoparticle delivery in CXCR4 colorectal cancer. *Acta Biomaterialia*, **2019**, 99, 426-432	10.8	9
273	High-Throughput Cell Motility Studies on Surface-Bound Protein Nanoparticles with Diverse Structural and Compositional Characteristics. *ACS Biomaterials Science and Engineering*, **2019**, 5, 5470-5480	5.5	4
272	Protein-driven nanomedicines in oncotherapy. *Current Opinion in Pharmacology*, **2019**, 47, 1-7	5.1	13
271	Engineering a recombinant chlorotoxin as cell-targeted cytotoxic nanoparticles. *Science China Materials*, **2019**, 62, 892-898	7.1	9
270	Efficient bioactive oligonucleotide-protein conjugation for cell-targeted cancer therapy. *ChemistryOpen*, **2019**, 8, 382-387	2.3	5

269	Targeting Antitumoral Proteins to Breast Cancer by Local Administration of Functional Inclusion Bodies. *Advanced Science*, **2019**, 6, 1900849	13.6	25
268	Nanostructure Empowers Active Tumor Targeting in Ligand-Based Molecular Delivery. *Particle and Particle Systems Characterization*, **2019**, 36, 1900304	3.1	7
267	Recruiting potent membrane penetrability in tumor cell-targeted protein-only nanoparticles. *Nanotechnology*, **2019**, 30, 115101	3.4	9
266	Bacterial inclusion bodies are industrially exploitable amyloids. *FEMS Microbiology Reviews*, **2019**, 43, 53-72	15.1	49
265	Assembly of histidine-rich protein materials controlled through divalent cations. *Acta Biomaterialia*, **2019**, 83, 257-264	10.8	35
264	Release of targeted protein nanoparticles from functional bacterial amyloids: A death star-like approach. *Journal of Controlled Release*, **2018**, 279, 29-39	11.7	24
263	Self-assembling toxin-based nanoparticles as self-delivered antitumoral drugs. *Journal of Controlled Release*, **2018**, 274, 81-92	11.7	41
262	Protein nanoparticles are nontoxic, tuneable cell stressors. *Nanomedicine*, **2018**, 13, 255-268	5.6	7
261	Improving Biomaterials Imaging for Nanotechnology: Rapid Methods for Protein Localization at Ultrastructural Level. *Biotechnology Journal*, **2018**, 13, e1700388	5.6	3
260	Conformational Conversion during Controlled Oligomerization into Nonamylogenic Protein Nanoparticles. *Biomacromolecules*, **2018**, 19, 3788-3797	6.9	15
259	Protein Nanoparticles Made of Recombinant Viral Antigens: A Promising Biomaterial for Oral Delivery of Fish Prophylactics. *Frontiers in Immunology*, **2018**, 9, 1652	8.4	7
258	Surface-Bound Gradient Deposition of Protein Nanoparticles for Cell Motility Studies. *ACS Applied Materials & Interfaces*, **2018**, 10, 25779-25786	9.5	7
257	Protein-Based Therapeutic Killing for Cancer Therapies. *Trends in Biotechnology*, **2018**, 36, 318-335	15.1	71
256	Intracellular trafficking of a dynein-based nanoparticle designed for gene delivery. *European Journal of Pharmaceutical Sciences*, **2018**, 112, 71-78	5.1	8
255	Selective depletion of metastatic stem cells as therapy for human colorectal cancer. *EMBO Molecular Medicine*, **2018**, 10,	12	47
254	A new approach to obtain pure and active proteins from Lactococcus lactis protein aggregates. *Scientific Reports*, **2018**, 8, 13917	4.9	24
253	Selective CXCR4 Cancer Cell Targeting and Potent Antineoplastic Effect by a Nanostructured Version of Recombinant Ricin. *Small*, **2018**, 14, e1800665	11	32
252	Switching cell penetrating and CXCR4-binding activities of nanoscale-organized arginine-rich peptides. *Nanomedicine: Nanotechnology, Biology, and Medicine*, **2018**, 14, 1777-1786	6	9

251	The fusogenic peptide HA2 impairs selectivity of CXCR4-targeted protein nanoparticles. *Chemical Communications*, **2017**, 53, 4565-4568	5.8	9
250	Bacterial Inclusion Bodies: Discovering Their Better Half. *Trends in Biochemical Sciences*, **2017**, 42, 726-737	10.3	90
249	Intrinsic functional and architectonic heterogeneity of tumor-targeted protein nanoparticles. *Nanoscale*, **2017**, 9, 6427-6435	7.7	18
248	Engineering tumor cell targeting in nanoscale amyloidal materials. *Nanotechnology*, **2017**, 28, 015102	3.4	20
247	Engineering multifunctional protein nanoparticles by in vitro disassembling and reassembling of heterologous building blocks. *Nanotechnology*, **2017**, 28, 505102	3.4	12
246	Peptide-Based Nanostructured Materials with Intrinsic Proapoptotic Activities in CXCR4+ Solid Tumors. *Advanced Functional Materials*, **2017**, 27, 1700919	15.6	27
245	Protein-only, antimicrobial peptide-containing recombinant nanoparticles with inherent built-in antibacterial activity. *Acta Biomaterialia*, **2017**, 60, 256-263	10.8	19
244	Functional protein-based nanomaterial produced in microorganisms recognized as safe: A new platform for biotechnology. *Acta Biomaterialia*, **2016**, 43, 230-239	10.8	34
243	Functional inclusion bodies produced in the yeast Pichia pastoris. *Microbial Cell Factories*, **2016**, 15, 166	6.4	26
242	Structural and functional features of self-assembling protein nanoparticles produced in endotoxin-free Escherichia coli. *Microbial Cell Factories*, **2016**, 15, 59	6.4	12
241	Cellular uptake and intracellular fate of protein releasing bacterial amyloids in mammalian cells. *Soft Matter*, **2016**, 12, 3451-60	3.6	30
240	Rational engineering of single-chain polypeptides into protein-only, BBB-targeted nanoparticles. *Nanomedicine: Nanotechnology, Biology, and Medicine*, **2016**, 12, 1241-51	6	24
239	Complex Particulate Biomaterials as Immunostimulant-Delivery Platforms. *PLoS ONE*, **2016**, 11, e0164073	3.7	13
238	Galactosidase-A Loaded-Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration. *Advanced Healthcare Materials*, **2016**, 5, 829-40	10.1	31
237	Bacterial mimetics of endocrine secretory granules as immobilized in vivo depots for functional protein drugs. *Scientific Reports*, **2016**, 6, 35765	4.9	24
236	CXCR4(+)-targeted protein nanoparticles produced in the food-grade bacterium Lactococcus lactis. *Nanomedicine*, **2016**, 11, 2387-98	5.6	10
235	Functional recruitment for drug delivery through protein-based nanotechnologies. *Nanomedicine*, **2016**, 11, 1333-6	5.6	17
234	Recombinant pharmaceuticals from microbial cells: a 2015 update. *Microbial Cell Factories*, **2016**, 15, 33	6.4	205

233	Conformational and functional variants of CD44-targeted protein nanoparticles bio-produced in bacteria. *Biofabrication*, **2016**, 8, 025001	10.5	15
232	Cancer-specific uptake of a liganded protein nanocarrier targeting aggressive CXCR4 colorectal cancer models. *Nanomedicine: Nanotechnology, Biology, and Medicine*, **2016**, 12, 1987-1996	6	29
231	Nanostructured recombinant cytokines: A highly stable alternative to short-lived prophylactics. *Biomaterials*, **2016**, 107, 102-14	15.6	31
230	Highly Versatile Polyelectrolyte Complexes for Improving the Enzyme Replacement Therapy of Lysosomal Storage Disorders. *ACS Applied Materials & Interfaces*, **2016**, 8, 25741-25752	9.5	16
229	Formulating tumor-homing peptides as regular nanoparticles enhances receptor-mediated cell penetrability. *Materials Letters*, **2015**, 154, 140-143	3.3	7
228	Annual acknowledgement of manuscript reviewers. *Microbial Cell Factories*, **2015**, 14, 34	6.4	78
227	Integrating mechanical and biological control of cell proliferation through bioinspired multieffector materials. *Nanomedicine*, **2015**, 10, 873-91	5.6	17
226	Detoxifying Escherichia coli for endotoxin-free production of recombinant proteins. *Microbial Cell Factories*, **2015**, 14, 57	6.4	129
225	Towards protein-based viral mimetics for cancer therapies. *Trends in Biotechnology*, **2015**, 33, 253-8	15.1	54
224	Targeting low-density lipoprotein receptors with protein-only nanoparticles. *Journal of Nanoparticle Research*, **2015**, 17, 1	2.3	2
223	Functional protein aggregates: just the tip of the iceberg. *Nanomedicine*, **2015**, 10, 2881-91	5.6	37
222	Engineering protein self-assembling in protein-based nanomedicines for drug delivery and gene therapy. *Critical Reviews in Biotechnology*, **2015**, 35, 209-21	9.4	40
221	Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model. *FASEB Journal*, **2015**, 29, 464-76	0.9	35
220	Bottom-Up Instructive Quality Control in the Biofabrication of Smart Protein Materials. *Advanced Materials*, **2015**, 27, 7816-22	24	47
219	A novel bio-functional material based on mammalian cell aggresomes. *Applied Microbiology and Biotechnology*, **2015**, 99, 7079-88	5.7	14
218	Strategies for the production of difficult-to-express full-length eukaryotic proteins using microbial cell factories: production of human alpha-galactosidase A. *Applied Microbiology and Biotechnology*, **2015**, 99, 5863-74	5.7	17
217	BBB-targeting, protein-based nanomedicines for drug and nucleic acid delivery to the CNS. *Biotechnology Advances*, **2015**, 33, 277-87	17.8	54
216	Bacterial inclusion body purification. *Methods in Molecular Biology*, **2015**, 1258, 293-305	1.4	11

215	Effect of the DnaK chaperone on the conformational quality of JCV VP1 virus-like particles produced in Escherichia coli. *Biotechnology Progress*, **2014**, 30, 744-8	2.8	2
214	Production of functional inclusion bodies in endotoxin-free Escherichia coli. *Applied Microbiology and Biotechnology*, **2014**, 98, 9229-38	5.7	40
213	Intracellular targeting of CD44+ cells with self-assembling, protein only nanoparticles. *International Journal of Pharmaceutics*, **2014**, 473, 286-95	6.5	33
212	Subcutaneous preconditioning increases invasion and metastatic dissemination in mouse colorectal cancer models. *DMM Disease Models and Mechanisms*, **2014**, 7, 387-96	4.1	8
211	Sheltering DNA in self-organizing, protein-only nano-shells as artificial viruses for gene delivery. *Nanomedicine: Nanotechnology, Biology, and Medicine*, **2014**, 10, 535-41	6	26
210	In vivo architectonic stability of fully de novo designed protein-only nanoparticles. *ACS Nano*, **2014**, 8, 4166-76	16.7	74
209	Topographically targeted osteogenesis of mesenchymal stem cells stimulated by inclusion bodies attached to polycaprolactone surfaces. *Nanomedicine*, **2014**, 9, 207-20	5.6	21
208	Biomedical Applications of Bacterial Inclusion Bodies **2014**, 203-220		3
207	Comparative analysis of lentiviral vectors and modular protein nanovectors for traumatic brain injury gene therapy. *Molecular Therapy - Methods and Clinical Development*, **2014**, 1, 14047	6.4	4
206	Recombinant protein materials for bioengineering and nanomedicine. *Nanomedicine*, **2014**, 9, 2817-28	5.6	26
205	Expanding the recombinant protein quality in Lactococcus lactis. *Microbial Cell Factories*, **2014**, 13, 167	6.4	20
204	Improving protein delivery of fibroblast growth factor-2 from bacterial inclusion bodies used as cell culture substrates. *Acta Biomaterialia*, **2014**, 10, 1354-9	10.8	29
203	Functionalization of 3D scaffolds with protein-releasing biomaterials for intracellular delivery. *Journal of Controlled Release*, **2013**, 171, 63-72	11.7	19
202	Multifunctional nanovesicle-bioactive conjugates prepared by a one-step scalable method using CO2-expanded solvents. *Nano Letters*, **2013**, 13, 3766-74	11.5	31
201	Overexpression of the nuclear factor kappaB inhibitor A20 is neurotoxic after an excitotoxic injury to the immature rat brain. *Neurological Research*, **2013**, 35, 308-19	2.7	6
200	Supramolecular organization of protein-releasing functional amyloids solved in bacterial inclusion bodies. *Acta Biomaterialia*, **2013**, 9, 6134-42	10.8	54
199	Unconventional microbial systems for the cost-efficient production of high-quality protein therapeutics. *Biotechnology Advances*, **2013**, 31, 140-53	17.8	99
198	Two-dimensional microscale engineering of protein-based nanoparticles for cell guidance. *ACS Nano*, **2013**, 7, 4774-84	16.7	29

197	A nanostructured bacterial bioscaffold for the sustained bottom-up delivery of protein drugs. *Nanomedicine*, **2013**, 8, 1587-99	5.6	25
196	Improved performance of protein-based recombinant gene therapy vehicles by tuning downstream procedures. *Biotechnology Progress*, **2013**, 29, 1458-63	2.8	1
195	Overexpression of the immunoreceptor CD300f has a neuroprotective role in a model of acute brain injury. *Brain Pathology*, **2012**, 22, 318-28	6	15
194	Bacterial inclusion bodies: making gold from waste. *Trends in Biotechnology*, **2012**, 30, 65-70	15.1	138
193	Recombinant Fab expression and secretion in Escherichia coli continuous culture at medium cell densities: Influence of temperature. *Process Biochemistry*, **2012**, 47, 446-452	4.8	21
192	Interleukin-10 overexpression does not synergize with the neuroprotective action of RGD-containing vectors after postnatal brain excitotoxicity but modulates the main inflammatory cell responses. *Journal of Neuroscience Research*, **2012**, 90, 143-59	4.4	3
191	Functional inclusion bodies produced in bacteria as naturally occurring nanopills for advanced cell therapies. *Advanced Materials*, **2012**, 24, 1742-7	24	62
190	RGD-based cell ligands for cell-targeted drug delivery act as potent trophic factors. *Nanomedicine: Nanotechnology, Biology, and Medicine*, **2012**, 8, 1263-6	6	16
189	Bioadhesiveness and efficient mechanotransduction stimuli synergistically provided by bacterial inclusion bodies as scaffolds for tissue engineering. *Nanomedicine*, **2012**, 7, 79-93	5.6	37
188	Disulfide bond formation and activation of Escherichia coli α-galactosidase under oxidizing conditions. *Applied and Environmental Microbiology*, **2012**, 78, 2376-85	4.8	8
187	Enzymatic characterization of highly stable human alpha-galactosidase A displayed on magnetic particles. *Biochemical Engineering Journal*, **2012**, 67, 20-27	4.2	10
186	Packaging protein drugs as bacterial inclusion bodies for therapeutic applications. *Microbial Cell Factories*, **2012**, 11, 76	6.4	47
185	Non-amyloidogenic peptide tags for the regulatable self-assembling of protein-only nanoparticles. *Biomaterials*, **2012**, 33, 8714-22	15.6	56
184	Intracellular CXCR4+ cell targeting with T22-empowered protein-only nanoparticles. *International Journal of Nanomedicine*, **2012**, 7, 4533-44	7.3	53
183	Nanopills: Functional Inclusion Bodies Produced in Bacteria as Naturally Occurring Nanopills for Advanced Cell Therapies (Adv. Mater. 13/2012). *Advanced Materials*, **2012**, 24, 1741-1741	24	
182	Inclusion bodies of fuculose-1-phosphate aldolase as stable and reusable biocatalysts. *Biotechnology Progress*, **2012**, 28, 421-7	2.8	15
181	Polyethylenimine-polyethyleneglycol-bis(aminoethylphosphate) nanoparticles mediated efficient DNA and siRNA transfection in mammalian cells. *Soft Matter*, **2011**, 7, 6103	3.6	7
180	Analytical approaches for assessing aggregation of protein biopharmaceuticals. *Current Pharmaceutical Biotechnology*, **2011**, 12, 1530-6	2.6	8

179	Recombinant protein quality evaluation: proposal for a minimal information standard. *Standards in Genomic Sciences*, **2011**, 5, 195-7		7
178	Biological role of bacterial inclusion bodies: a model for amyloid aggregation. *FEBS Journal*, **2011**, 278, 2419-27	5.7	57
177	Biological activities of histidine-rich peptides; merging biotechnology and nanomedicine. *Microbial Cell Factories*, **2011**, 10, 101	6.4	40
176	Environmental quality of mussel farms in the Vigo estuary: pollution by PAHs, origin and effects on reproduction. *Environmental Pollution*, **2011**, 159, 250-265	9.3	63
175	Co-production of GroELS discriminates between intrinsic and thermally-induced recombinant protein aggregation during substrate quality control. *Microbial Cell Factories*, **2011**, 10, 79	6.4	7
174	Influence of growth temperature on the production of antibody Fab fragments in different microbes: a host comparative analysis. *Biotechnology Progress*, **2011**, 27, 38-46	2.8	37
173	Integrated approach to produce a recombinant, His-tagged human α-galactosidase A in mammalian cells. *Biotechnology Progress*, **2011**, 27, 1206-17	2.8	13
172	How to break recombinant bacteria: does it matter?. *Bioengineered Bugs*, **2011**, 2, 222-5		6
171	Nanoparticulate architecture of protein-based artificial viruses is supported by protein-DNA interactions. *Nanomedicine*, **2011**, 6, 1047-61	5.6	11
170	Cross-system excision of chaperone-mediated proteolysis in chaperone-assisted recombinant protein production. *Bioengineered Bugs*, **2010**, 1, 148-50		
169	Protein nanodisk assembling and intracellular trafficking powered by an arginine-rich (R9) peptide. *Nanomedicine*, **2010**, 5, 259-68	5.6	53
168	Nanostructured bacterial materials for innovative medicines. *Trends in Microbiology*, **2010**, 18, 423-30	12.4	88
167	Protein aggregation and soluble aggregate formation screened by a fast microdialysis assay. *Journal of Biomolecular Screening*, **2010**, 15, 453-7		9
166	Tunable geometry of bacterial inclusion bodies as substrate materials for tissue engineering. *Nanotechnology*, **2010**, 21, 205101	3.4	58
165	Friendly production of bacterial inclusion bodies. *Korean Journal of Chemical Engineering*, **2010**, 27, 385-389	1.2	17
164	DnaK/DnaJ-assisted recombinant protein production in Trichoplusia ni larvae. *Applied Microbiology and Biotechnology*, **2010**, 86, 633-9	5.7	7
163	Side effects of chaperone gene co-expression in recombinant protein production. *Microbial Cell Factories*, **2010**, 9, 64	6.4	71
162	Integrated Approach to Optimize Transient Gene Expression in Mammalian Cells: Production of a Recombinant Human Alpha-galactosidase A. *Journal of Biotechnology*, **2010**, 150, 436-437	3.7	

161	The nanoscale properties of bacterial inclusion bodies and their effect on mammalian cell proliferation. *Biomaterials*, **2010**, 31, 5805-12	15.6	60
160	Internalization and kinetics of nuclear migration of protein-only, arginine-rich nanoparticles. *Biomaterials*, **2010**, 31, 9333-9	15.6	19
159	Isolation of cell-free bacterial inclusion bodies. *Microbial Cell Factories*, **2010**, 9, 71	6.4	63
158	Discriminating foot-and-mouth disease virus-infected and vaccinated animals by use of beta-galactosidase allosteric biosensors. *Vaccine Journal*, **2009**, 16, 1228-35		7
157	Modular protein engineering in emerging cancer therapies. *Current Pharmaceutical Design*, **2009**, 15, 893-916	3.3	31
156	Rehosting of bacterial chaperones for high-quality protein production. *Applied and Environmental Microbiology*, **2009**, 75, 7850-4	4.8	18
155	Biomedical applications of distally controlled magnetic nanoparticles. *Trends in Biotechnology*, **2009**, 27, 468-76	15.1	226
154	Peptide-mediated DNA condensation for non-viral gene therapy. *Biotechnology Advances*, **2009**, 27, 432-8	7.8	66
153	Surface Cell Growth Engineering Assisted by a Novel Bacterial Nanomaterial. *Advanced Materials*, **2009**, 21, 4249-4253	24	64
152	Screening HIV-1 antigenic peptides as receptors for antibodies and CD4 in allosteric nanosensors. *Journal of Molecular Recognition*, **2009**, 22, 255-60	2.6	4
151	Fast electrochemical detection of anti-HIV antibodies: coupling allosteric enzymes and disk microelectrode arrays. *Analytica Chimica Acta*, **2009**, 641, 1-6	6.6	23
150	Microbial factories for recombinant pharmaceuticals. *Microbial Cell Factories*, **2009**, 8, 17	6.4	288
149	Systems-Level Analysis of Protein Quality in Inclusion Body-Forming Escherichia coli Cells **2009**, 295-326		1
148	Peptide-assisted traffic engineering for nonviral gene therapy. *Drug Discovery Today*, **2008**, 13, 1067-74	8.8	36
147	Protein folding and conformational stress in microbial cells producing recombinant proteins: a host comparative overview. *Microbial Cell Factories*, **2008**, 7, 11	6.4	229
146	The scientific impact of microbial cell factories. *Microbial Cell Factories*, **2008**, 7, 33	6.4	2
145	Membrane-active peptides for non-viral gene therapy: making the safest easier. *Trends in Biotechnology*, **2008**, 26, 267-75	15.1	77
144	Localization of Functional Polypeptides in Bacterial Inclusion Bodies. *Applied and Environmental Microbiology*, **2008**, 74, 1960-1960	4.8	1

143	The Functional quality of soluble recombinant polypeptides produced in Escherichia coli is defined by a wide conformational spectrum. *Applied and Environmental Microbiology*, **2008**, 74, 7431-3	4.8	29
142	Antiretroviral therapy-induced functional modification of IgG4 and IgM responses in HIV-1-infected individuals screened by an allosteric biosensor. *Journal of Biomolecular Screening*, **2008**, 13, 817-21		4
141	In situ protein folding and activation in bacterial inclusion bodies. *Biotechnology and Bioengineering*, **2008**, 100, 797-802	4.9	26
140	Yield, solubility and conformational quality of soluble proteins are not simultaneously favored in recombinant Escherichia coli. *Biotechnology and Bioengineering*, **2008**, 101, 1353-8	4.9	36
139	Recombinant protein production in the new Millennium. *Microbial Cell Factories*, **2007**, 6, 33	6.4	2
138	The conformational quality of insoluble recombinant proteins is enhanced at low growth temperatures. *Biotechnology and Bioengineering*, **2007**, 96, 1101-6	4.9	152
137	RGD domains neuroprotect the immature brain by a glial-dependent mechanism. *Annals of Neurology*, **2007**, 62, 251-61	9.4	15
136	Allosteric molecular sensing of anti-HIV antibodies by an immobilized engineered □galactosidase. *Enzyme and Microbial Technology*, **2007**, 41, 492-497	3.8	3
135	Recombinant protein solubility - does more mean better?. *Nature Biotechnology*, **2007**, 25, 718-20	44.5	104
134	Role of the chaperone DnaK in protein solubility and conformational quality in inclusion body-forming Escherichia coli cells. *FEMS Microbiology Letters*, **2007**, 273, 187-95	2.9	42
133	Localization of functional polypeptides in bacterial inclusion bodies. *Applied and Environmental Microbiology*, **2007**, 73, 289-94	4.8	93
132	Analysis of recombinant protein toxicity in E. coli through a phage lambda-based genetic screening system. *Biotechnology Letters*, **2007**, 29, 1381-6	3	5
131	Amyloid-linked cellular toxicity triggered by bacterial inclusion bodies. *Biochemical and Biophysical Research Communications*, **2007**, 355, 637-42	3.4	19
130	Divergent genetic control of protein solubility and conformational quality in Escherichia coli. *Journal of Molecular Biology*, **2007**, 374, 195-205	6.5	80
129	Protein quality in bacterial inclusion bodies. *Trends in Biotechnology*, **2006**, 24, 179-85	15.1	271
128	Neuroprotection from NMDA excitotoxic lesion by Cu/Zn superoxide dismutase gene delivery to the postnatal rat brain by a modular protein vector. *BMC Neuroscience*, **2006**, 7, 35	3.2	26
127	Enhanced molecular recognition signal in allosteric biosensing by proper substrate selection. *Biotechnology and Bioengineering*, **2006**, 94, 193-9	4.9	7
126	Cellular toxicity triggered by bacterial inclusion bodies. *Microbial Cell Factories*, **2006**, 5, P9	6.4	

125	Efficient, antibody-mediated allosteric activation of an immobilized, E. coli beta-galactosidase recombinant biosensor. *Microbial Cell Factories*, **2006**, 5, P43	6.4	
124	Performance of beta-galactosidase inclusion bodies in enzymatic bioprocesses. *Microbial Cell Factories*, **2006**, 5, P14	6.4	
123	Comparative analysis of E. coli inclusion bodies and thermal protein aggregates. *Microbial Cell Factories*, **2006**, 5, P16	6.4	1
122	Insertional protein engineering for analytical molecular sensing. *Microbial Cell Factories*, **2006**, 5, 15	6.4	23
121	The chaperone DnaK controls the fractioning of functional protein between soluble and insoluble cell fractions in inclusion body-forming cells. *Microbial Cell Factories*, **2006**, 5, 26	6.4	36
120	High-throughput, functional screening of the anti-HIV-1 humoral response by an enzymatic nanosensor. *Molecular Immunology*, **2006**, 43, 2119-23	4.3	14
119	Protein Inclusion Bodies in Recombinant Bacteria **2006**, 237-292		7
118	Lon and ClpP proteases participate in the physiological disintegration of bacterial inclusion bodies. *Journal of Biotechnology*, **2005**, 119, 163-71	3.7	25
117	Bacterial inclusion bodies are cytotoxic in vivo in absence of functional chaperones DnaK or GroEL. *Journal of Biotechnology*, **2005**, 118, 406-12	3.7	29
116	Amyloid-like properties of bacterial inclusion bodies. *Journal of Molecular Biology*, **2005**, 347, 1025-37	6.5	191
115	Engineering the E. coli beta-galactosidase for the screening of antiviral protease inhibitors. *Biochemical and Biophysical Research Communications*, **2005**, 329, 453-6	3.4	3
114	Focusing in bioproduction science. *Microbial Cell Factories*, **2005**, 4, 10	6.4	
113	Aggregation as bacterial inclusion bodies does not imply inactivation of enzymes and fluorescent proteins. *Microbial Cell Factories*, **2005**, 4, 27	6.4	217
112	Folding of a misfolding-prone beta-galactosidase in absence of DnaK. *Biotechnology and Bioengineering*, **2005**, 90, 869-75	4.9	31
111	A mathematical approach to molecular organization and proteolytic disintegration of bacterial inclusion bodies. *Mathematical Medicine and Biology*, **2005**, 22, 209-26	1.3	5
110	Localization of chaperones DnaK and GroEL in bacterial inclusion bodies. *Journal of Bacteriology*, **2005**, 187, 3599-601	3.5	90
109	Modular protein engineering for non-viral gene therapy. *Trends in Biotechnology*, **2004**, 22, 371-7	15.1	43
108	The impact of dnaKJ overexpression on recombinant protein solubility results from antagonistic effects on the control of protein quality. *Biotechnology Letters*, **2004**, 26, 595-601	3	11

107	A new editorial board for a new editorial period. *Microbial Cell Factories*, **2004**, 3, 3	6.4	1
106	Profiling the allosteric response of an engineered beta-galactosidase to its effector, anti-HIV antibody. *Biochemical and Biophysical Research Communications*, **2004**, 314, 854-60	3.4	15
105	Protein aggregation in recombinant bacteria: biological role of inclusion bodies. *Biotechnology Letters*, **2003**, 25, 1385-95	3	245
104	Engineering of Escherichia coli beta-galactosidase for solvent display of a functional scFv antibody fragment. *FEBS Letters*, **2003**, 533, 115-8	3.8	5
103	Role of molecular chaperones in inclusion body formation. *FEBS Letters*, **2003**, 537, 215-21	3.8	75
102	Allosteric enzymes as biosensors for molecular diagnosis. *FEBS Letters*, **2003**, 554, 169-72	3.8	39
101	Engineering nuclear localization signals in modular protein vehicles for gene therapy. *Biochemical and Biophysical Research Communications*, **2003**, 304, 625-31	3.4	30
100	Nonviral gene delivery to the central nervous system based on a novel integrin-targeting multifunctional protein. *Human Gene Therapy*, **2003**, 14, 1215-23	4.8	20
99	Control of Escherichia coli growth rate through cell density. *Microbiological Research*, **2002**, 157, 257-65	5.3	19
98	Enhanced response to antibody binding in engineered beta-galactosidase enzymatic sensors. *BBA - Proteins and Proteomics*, **2002**, 1596, 212-24		20
97	Connection between gene dosage and protein stability revealed by a high-yield production of recombinant proteins in an E. coli LexA1(Ind-) background. *Biotechnology and Bioengineering*, **2002**, 78, 722-30	4.9	5
96	Tailoring molecular sensing for peptide displaying engineered enzymes. *Biotechnology Letters*, **2002**, 24, 469-477	3	5
95	Co-activation of antibody-responsive, enzymatic sensors by a recombinant scFv antibody fragment produced in E. coli. *Biotechnology Letters*, **2002**, 24, 1543-1551	3	6
94	Protein aggregated into bacterial inclusion bodies does not result in protection from proteolytic digestion. *Biotechnology Letters*, **2002**, 24, 1939-1944	3	10
93	Old bugs for new tasks; the microbial offer in the proteomics era. *Microbial Cell Factories*, **2002**, 1, 4	6.4	3
92	Construction and deconstruction of bacterial inclusion bodies. *Journal of Biotechnology*, **2002**, 96, 3-12	3.7	173
91	Variable specific activity ofEscherichia coli?-galactosidase in bacterial cells. *Biotechnology and Bioengineering*, **2001**, 72, 255-260	4.9	11
90	Plasmid maintenance and recombinant cell fitness explored in bacterial colonies. *Biotechnology Letters*, **2001**, 23, 831-838	3	1

89	Cell lysis in Escherichia coli cultures stimulates growth and biosynthesis of recombinant proteins in surviving cells. *Microbiological Research*, **2001**, 156, 13-8	5.3	14
88	Phage spread dynamics in clonal bacterial populations is depending on features of the founder cell. *Microbiological Research*, **2001**, 156, 35-40	5.3	
87	Engineering regulable Escherichia coli beta-galactosidases as biosensors for anti-HIV antibody detection in human sera. *Journal of Biological Chemistry*, **2001**, 276, 40087-95	5.4	30
86	In situ proteolytic digestion of inclusion body polypeptides occurs as a cascade process. *Biochemical and Biophysical Research Communications*, **2001**, 282, 436-41	3.4	14
85	Efficient accommodation of recombinant, foot-and-mouth disease virus RGD peptides to cell-surface integrins. *Biochemical and Biophysical Research Communications*, **2001**, 285, 201-6	3.4	13
84	Protein aggregation as bacterial inclusion bodies is reversible. *FEBS Letters*, **2001**, 489, 29-33	3.8	109
83	Variable specific activity of Escherichia coli beta-galactosidase in bacterial cells. *Biotechnology and Bioengineering*, **2001**, 72, 255-60	4.9	2
82	Exploiting viral cell-targeting abilities in a single polypeptide, non-infectious, recombinant vehicle for integrin-mediated DNA delivery and gene expression. *Biotechnology and Bioengineering*, **2000**, 68, 689-96	4.9	26
81	Molecular mechanisms for antibody-mediated modulation of peptide-displaying enzyme sensors. *Biochemical and Biophysical Research Communications*, **2000**, 275, 360-4	3.4	18
80	Molecular organization of protein-DNA complexes for cell-targeted DNA delivery. *Biochemical and Biophysical Research Communications*, **2000**, 278, 455-61	3.4	29
79	Fine architecture of bacterial inclusion bodies. *FEBS Letters*, **2000**, 471, 7-11	3.8	103
78	Corrigendum to: distinct mechanisms of antibody-mediated enzymatic reactivation in beta-galactosidase molecular sensors. *FEBS Letters*, **2000**, 473, 123	3.8	6
77	Successful mimicry of a complex viral antigen by multiple peptide insertions in a carrier protein. *FEBS Letters*, **2000**, 474, 87-92	3.8	3
76	RecA-dependent viral burst in bacterial colonies during the entry into stationary phase. *FEMS Microbiology Letters*, **1999**, 170, 313-317	2.9	4
75	Heat-inactivation of plasmid-encoded CI857 repressor induces gene expression from Ind- lambda prophage in recombinant Escherichia coli. *FEMS Microbiology Letters*, **1999**, 177, 327-34	2.9	4
74	Distinct chaperone affinity to folding variants of homologous recombinant proteins. *Biotechnology Letters*, **1999**, 21, 531-536	3	5
73	Proteolytic digestion of bacterial inclusion body proteins during dynamic transition between soluble and insoluble forms. *BBA - Proteins and Proteomics*, **1999**, 1434, 170-6		32
72	Secretion-dependent proteolysis of heterologous protein by recombinant Escherichia coli is connected to an increased activity of the energy-generating dissimilatory pathway **1999**, 66, 61-67		27

71	The expression of recombinant genes from bacteriophage lambda strong promoters triggers the SOS response in escherichia coli. *Biotechnology and Bioengineering*, **1999**, 64, 127	4.9	3
70	Tolerance of Escherichia coli beta-galactosidase C-terminus to different-sized fusions. *Biotechnology and Bioengineering*, **1999**, 64, 644-9	4.9	9
69	RecA-dependent viral burst in bacterial colonies during the entry into stationary phase. *FEMS Microbiology Letters*, **1999**, 170, 313-7	2.9	4
68	Detection of molecular interactions by using a new peptide-displaying bacteriophage biosensor. *Biochemical and Biophysical Research Communications*, **1999**, 262, 801-5	3.4	4
67	Dynamics of in vivo protein aggregation: building inclusion bodies in recombinant bacteria. *FEMS Microbiology Letters*, **1998**, 169, 9-15	2.9	62
66	Optimized release of recombinant proteins by ultrasonication of E. coli cells. *Biotechnology and Bioengineering*, **1998**, 58, 536-40	4.9	84
65	Plasmid maintenance in Escherichia coli recombinant cultures is dramatically, steadily, and specifically influenced by features of the encoded proteins **1998**, 58, 625-632		69
64	A cell adhesion peptide from foot-and-mouth disease virus can direct cell targeted delivery of a functional enzyme. *Biotechnology and Bioengineering*, **1998**, 59, 294-301	4.9	7
63	The expression of recombinant genes from bacteriophage lambda strong promoters triggers the SOS response in Escherichia coli. *Biotechnology and Bioengineering*, **1998**, 60, 551-9	4.9	26
62	Dynamics of in vivo protein aggregation: building inclusion bodies in recombinant bacteria. *FEMS Microbiology Letters*, **1998**, 169, 9-15	2.9	55
61	Unfolding of bacteriophage P22 tailspike protein: enhanced thermal stability of an N-terminal fusion mutant. *FEBS Letters*, **1998**, 432, 228-30	3.8	6
60	Engineering of solvent-exposed loops in Escherichia coli beta-galactosidase. *FEBS Letters*, **1998**, 434, 23-7	3.8	41
59	Distinct mechanisms of antibody-mediated enzymatic reactivation in beta-galactosidase molecular sensors. *FEBS Letters*, **1998**, 438, 267-71	3.8	21
58	Insertional mutagenesis in the tailspike protein of bacteriophage P22. *Biochemical and Biophysical Research Communications*, **1998**, 244, 428-33	3.4	9
57	Display-induced antigenic variation in recombinant peptides. *Biochemical and Biophysical Research Communications*, **1998**, 248, 773-7	3.4	7
56	Conformational flexibility in a highly mobile protein loop of foot-and-mouth disease virus: distinct structural requirements for integrin and antibody binding. *Journal of Molecular Biology*, **1998**, 283, 331-8	6.5	20
55	Limited in vivo proteolysis of aggregated proteins. *Biochemical and Biophysical Research Communications*, **1997**, 237, 325-30	3.4	34
54	Viral spread within ageing bacterial populations. *Gene*, **1997**, 202, 147-9	3.8	9

53	Reversible activation of a cryptic cleavage site within E. coli beta-galactosidase in beta-galactosidase fusion proteins. *BBA - Proteins and Proteomics*, **1997**, 1343, 221-6		8
52	Secretion-dependent proteolysis of recombinant proteins is associated with inhibition of cell growth in Escherichia coli. *Biotechnology Letters*, **1997**, 19, 373-378	3	11
51	Enhanced fitness of recombinant protein synthesis in the stationary phase of Escherichia coli batch cultures. *Biotechnology Letters*, **1997**, 19, 225-228	3	7
50	Antigenicity of VP60 structural protein of rabbit haemorrhagic disease virus. *Archives of Virology*, **1997**, 142, 1843-8	2.6	7
49	The position of the heterologous domain can influence the solubility and proteolysis of beta-galactosidase fusion proteins in E. coli. *Journal of Biotechnology*, **1996**, 48, 191-200	3.7	59
48	Peptide display on functional tailspike protein of bacteriophage P22. *Gene*, **1996**, 176, 225-9	3.8	9
47	Converging antigenic structure of a recombinant viral peptide displayed on different frameworks of carrier proteins. *FEBS Letters*, **1996**, 397, 169-72	3.8	4
46	A recombinant, arginine-glycine-aspartic acid (RGD) motif from foot-and-mouth disease virus binds mammalian cells through vitronectin and, to a lower extent, fibronectin receptors. *Gene*, **1996**, 180, 101-6	3.8	20
45	Microheterogeneity of p60 capsid protein and the encoding gene among contemporary isolates of rabbit hemorrhagic disease virus. *Virus Genes*, **1996**, 12, 189-92	2.3	8
44	Antigenicity of a viral peptide displayed on beta-galactosidase fusion proteins is influenced by the presence of the homologous partner protein. *FEMS Microbiology Letters*, **1996**, 145, 77-82	2.9	2
43	Polylinker-encoded peptides can confer toxicity to recombinant proteins produced in Escherichia coli. *Biotechnology Progress*, **1996**, 12, 723-7	2.8	12
42	Beta-galactosidase enzymatic activity as a molecular probe to detect specific antibodies. *Journal of Biological Chemistry*, **1996**, 271, 21251-6	5.4	45
41	Peptide insertions in β-galactosidase activating interface can improve binding in TPEG-Sepharose affinity chromatography. *Biotechnology Letters*, **1995**, 9, 767-770		2
40	Induced mutagenesis by bleomycin in the purple sulfur bacterium Thiocapsa roseopersicina. *Current Microbiology*, **1995**, 30, 117-20	2.4	5
39	Improved mimicry of a foot-and-mouth disease virus antigenic site by a viral peptide displayed on beta-galactosidase surface. *Bio/technology*, **1995**, 13, 801-4		47
38	A recombinant foot-and-mouth disease virus antigen inhibits DNA replication and triggers the SOS response in Escherichia coli. *FEMS Microbiology Letters*, **1995**, 129, 157-62	2.9	8
37	Mitomycin C stimulates thermally induced recombinant gene expression in Escherichia coli MC strains. *Applied Microbiology and Biotechnology*, **1995**, 42, 890-4	5.7	
36	A recombinant foot-and-mouth disease virus antigen inhibits DNA replication and triggers the SOS response in. *FEMS Microbiology Letters*, **1995**, 129, 157-162	2.9	6

35	An optimized ultrasonication protocol for bacterial cell disruption and recovery of -galactosidase fusion proteins. *Biotechnology Letters*, **1994**, 8, 509		21
34	Production of thermally induced recombinant proteins relative to cell biomass is influenced by cell density in Escherichia coli batch cultures. *Biotechnology Letters*, **1994**, 16, 777-782	3	2
33	Insertion of a 27 amino acid viral peptide in different zones of Escherichia coli beta-galactosidase: effects on the enzyme activity. *FEMS Microbiology Letters*, **1994**, 123, 107-12	2.9	17
32	Ammonium-mediated reduction of plasmid copy number and recombinant gene expression in Escherichia coli. *Biotechnology Progress*, **1994**, 10, 648-51	2.8	14
31	Enhanced production of pL-controlled recombinant proteins and plasmid stability in Escherichia coli RecA+ strains. *Journal of Biotechnology*, **1993**, 29, 299-306	3.7	29
30	Uses of beta-galactosidase tag in on-line monitoring production of fusion proteins and gene expression in Escherichia coli. *Enzyme and Microbial Technology*, **1993**, 15, 66-71	3.8	21
29	Conditions for a continuous production of transient microbial products in a two-stage fermentation system. *Biotechnology Letters*, **1993**, 15, 827	3	4
28	Inhibition of CI857-controlled recombinant gene expression in Escherichia coli at very low concentrations of glucose. *Biotechnology Letters*, **1993**, 15, 549-552	3	2
27	Fine regulation of cI857-controlled gene expression in continuous culture of recombinant Escherichia coli by temperature. *Applied and Environmental Microbiology*, **1993**, 59, 3485-7	4.8	58
26	Transport properties in dense fluids and their binary mixtures. *Fluid Phase Equilibria*, **1992**, 79, 277-288	2.5	1
25	SOS system induction in Escherichia coli cells with distinct levels of ribonucleotide reductase activity. *Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis*, **1992**, 281, 137-41		1
24	Simultaneous on line monitoring of intracellular -galactosidase activity and biomass using flow injection analysis inEscherichia coli batch fermentations. *Biotechnology Letters*, **1992**, 6, 213-218		6
23	A model for continuous production of thermally induced recombinant proteins. *Biotechnology Letters*, **1991**, 13, 249-254	3	1
22	Molecular cloning and expression of the VP1 gene of foot-and-mouth disease virus C1 in E. coli: effect on bacterial cell viability. *Applied Microbiology and Biotechnology*, **1991**, 35, 788-92	5.7	18
21	Assay of -galactosidase activity by Flow Injection Analysis (FIA). *Biotechnology Letters*, **1991**, 5, 389		3
20	Prediction of transport properties for Lennard-Jones fluids and their binary mixtures using the effective-diameter hard-sphere kinetic theory. *Molecular Physics*, **1991**, 74, 1315-1334	1.7	11
19	Fixation of mutations at the VP1 gene of foot-and-mouth disease virus. Can quasispecies define a transient molecular clock?. *Gene*, **1991**, 103, 147-53	3.8	40
18	Evidence for a specific regulation of recA gene transcription in Escherichia coli. *Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis*, **1988**, 199, 123-30	3.3	2

17	Evidence for a specific regulation of recA gene transcription in Escherichia coli. *Mutation Research - Environmental Mutagenesis and Related Subjects Including Methodology*, **1988**, 199, 123-130		
16	3D gene of foot-and-mouth disease virus. Conservation by convergence of average sequences. *Journal of Molecular Biology*, **1988**, 204, 771-6	6.5	23
15	Coevolution of cells and viruses in a persistent infection of foot-and-mouth disease virus in cell culture. *Journal of Virology*, **1988**, 62, 2050-8	6.6	109
14	Activated RecA protein may induce expression of a gene that is not controlled by the LexA repressor and whose function is required for mutagenesis and repair of UV-irradiated bacteriophage lambda. *Journal of Bacteriology*, **1987**, 169, 4816-21	3.5	15
13	Induction of the SOS response by hydroxyurea in Escherichia coli K12. *Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis*, **1987**, 192, 105-8		15
12	Expression of the SOS system in Escherichia coli growing under nitrate respiration conditions. *Antonie Van Leeuwenhoek*, **1986**, 52, 63-74	2.1	1
11	ATP Production after ultraviolet irradiation inEscherichia coli. *Current Microbiology*, **1986**, 14, 31-34	2.4	8
10	Effect of P22-mediated receptor release and of phage DNA injection on cell viability of Salmonella typhimurium. *Journal of General Virology*, **1986**, 67 (Pt 11), 2561-4	4.9	
9	ATP hydrolysis during SOS induction in Escherichia coli. *Journal of Bacteriology*, **1986**, 167, 1055-7	3.5	20
8	Effect of adenine, cytidine and guanosine on the expression of the SOS system in Escherichia coli. *Microbiology (United Kingdom)*, **1985**, 131, 113-8	2.9	5
7	Changes in ATP concentration in Escherichia coli during induction of the SOS system by mitomycin C and bleomycin. *Microbiology (United Kingdom)*, **1984**, 130, 2247-51	2.9	9
6	Evolution of cellular ATP concentration after UV-mediated induction of SOS system in Escherichia coli. *Biochemical and Biophysical Research Communications*, **1983**, 117, 556-61	3.4	30
5	Further characterization of the expression of SOS functions in recA430 mutants of Escherichia coli. *Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis*, **1983**, 121, 171-5		7
4	Indirect induction of SOS functions in Salmonella typhimurium. *Antonie Van Leeuwenhoek*, **1983**, 49, 471-84	2.1	3
3	Cell death induced by phage at high multiplicity of infection is not due to lysis inSalmonella typhimurium. *FEMS Microbiology Letters*, **1982**, 15, 291-294	2.9	1
2	Proteine Bolognese. *Modelling in Science Education and Learning*,4, 159	0.1	
1	The spectrum of building block conformers sustains the biophysical properties of clinically-oriented self-assembling protein nanoparticles. *Science China Materials*,1	7.1	1